- Occupancy improvement in Q2 - Management open for more accretion - 2025e P/CEPS at 14x, ~12.
Beijer Alma har genomfört fyra förvärv i år, varav ett under det andra kvartalet.
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items thi...
The company posted a trading statement in late June.
Redeye provides an initial take on Waystream’s Q2 numbers that were presented this morning, which ca...
Redeye comments on Modelons’ proposed directed share issue of SEK20m at SEK20 per share, representin...
Redeye comments on Invisio ahead of Q2-results (due 18 July) where we expect sequential improvement ...
Redeye shares its thoughts and fine-tunes its estimates ahead of CTEK’s Q2 report, which is due Thur...
Redeye publishes a preview of Transtema’s Q2 report.
- Report out 18 July - Q2e: sales SEK 37m, -3% y-o-y, EBIT SEK -0.
Redeye positively views yesterday’s press release from Acarix announcing that it has secured its fir...
Redeye comments on OncoZenge’s announcement of a SEK7.
Redeye comments on Litium’s Q2 report, returning to a solid ARR growth of 12%.
Redeye provides a short comment on the trading update from Cheffelo, released this morning.
- SEK 72m follow-up order (Terminals) from Swedish FMV - Deliveries start in Q3 - Could add ~10% to ...
Det var ännu en väntat stark och stabil rapport som Eastnine kom med för det andra kvartalet.
The company sells its Marine and Offshore Unit for EUR 7.
Redeye comments on Vertiseit’s acquisition of MDT. As the price is reasonable and the SEK20m in ARR ...
Redeye comments on Isofol’s recently announced rights issue outcome.
Redeye comments on the preliminary Q2 figures showing a weak development in Fiber Solutions, questio...